Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Jordan Berlin

12 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCMD15110

04/05/2016

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Treatment

VICCPHI1531

03/01/2016

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers

Treatment

VICCGI1515

01/05/2016

A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients with Advanced Solid Tumors

Treatment

VICCPHI1598

12/10/2015

A Phase 1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 and MM-121 in Heregulin Positive Cancer Patients

Treatment

VICCPHI1588

11/27/2015

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

Treatment

VICCPHI14126

09/03/2015

An OpenLabel Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of VX803 as a Single Agent and in Combination With Carboplatin in Subjects With Advanced Solid Tumors or Lymphoma.

Treatment

VICCGIP1520

07/21/2015

A Phase 1, Open Label, Non Randomized, Dose Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS 102 in Combination with CPT 11 and Bevacizumab In Patients with Advanced Gastrointestinal Tumors

Treatment

VICCPHI14136

07/02/2015

An Open-Label, Phase I, Dose-Escalation Trial to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti- FGFR2 Antibody Drug Conjugate BAY 1187982 in Subjects with Advanced Solid Tumors Known to Express FGFR2

Treatment

VICCPHI1436

08/18/2014

A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination with Paclitaxel in Patients with Advanced Solid Tumors

Treatment

VICCGI1370

12/30/2013

A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer

Treatment

VICCGI1250

04/09/2013

A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)

Treatment

VICCPHI1138

03/08/2012

A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies